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RECOVERY AND RECHALLENGE AFTER THE NEUROLEPTIC 
MALIGNANT SYNDROME 
MOHIT P. CHOPRA & R. RAGURAM 
ABSTRACT 
The Neuroleptic Malignant Syndrome (NMS) can have a complicated recovery and rechallenging 
these patients is fraught with risks of recurrence. We examined our data from a sequential case 
series of NMS over a four-year period for details about treatment, complications and rechallenge. 
Duration of NMS when treated with one versus two dopamine agonists, and neuroleptic loading rates 
before NMS and on rechallenge were compared using the chi-square test with correction. Duration of 
NMS was found to be longer when treated with more than one agonist. The mean loading rate on re-
challenge. attempted in six patients, was not found tc be statistically different from that resulting in 
NMS However, two patients (33%) re-challenged with high-potency neuroleptics at high loading rates 
experienced partial recurrence. Our findings show no advantage for treating NMS with multiple agents 
and emphasize the need for a cautious dosing strategy while re-challenging patients with typical 
neuroleptics. 
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The Neuroleptic Malignant Syndrome 
(NMS) is a potentially fatal complication of 
antipsychotic medication, with reviews reporting 
a continued mortality of over 10% from the 
syndrome (Caroff and Mann, 1988; Shalev et 
al .1989). There is also increasing evidence that 
patients who recover may suffer long term 
neurologic and cognitive sequelae after NMS 
(Koponen et al ,1991; Rothke and Bush.1986). 
Re-challenging patients in need of maintenance 
neuroleptics is fraught with risks of recurrence 
(Shalev et ai., 1986). Guidelines recommend 
gradual rechallenge with neuroleptics of lower 
potency, and no information is available in literature 
about the consequences should re-challenge 
occur with neuroleptics of similar or higher potency 
(Caroff and Mann. 1993). We recently published 
a case-control study of sequentially developing 
cases of NMS over a four-year period at our centre 
(Chopra etal, 1999) The significant finding of our 
study was a mortality rate that was higher than 
that reported in literature. In an effort to further 
explore the possible relevance of this finding in 
our context, we examined our database for 
information regarding complications and treatment 
during NMS in the patient cohort. Information 
pertaining to re-challenge after recovery from NMS 
was also analyzed 
MATERIAL AND METHOD 
The study examined sequentially developing 
cases of NMS at the January 1, 1990 and 
December 31,1993 These patients were identified 
from Intensive Care Unit (ICU) records, where any 
patient diagnosed with NMS is treated. The 
diagnosis was confirmed using Caroff and Mann's 
(1993) criteria for NMS Information about these 
cases was recorded on a 70-item proforma, and 
the neuroleptic dose was converted to 
chlorpromazine dose equivalents (CPZ-Eq) using 
the method described by Shalev and Munitz (1986). 
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Information pertaining to treatment, 
complications and re-challenge was examined 
for the purposes of the current study. The 
methodology and patient characteristics are 
described in detail in our earlier paper (Chopra et 
al ,1999). Patient subgroups were compared for 
mean time to recovery with treatment with one 
versus two dopaminergic agonists, as well as 
for mean loading rates at the time of developing 
NMS and upon re-challenge using the chi-square 
test with correction for small samples. 
RESULTS 
Thirteen patients, with a mean age of 29.5 
(±9.9) years and M : F ratio of 3.1 had developed 
NMS during the period of the study Five of these 
patients (38.5%) had a fatal outcome. 
Medications used to treat the episodes of 
NMS are shown in table 1. The mean time to 
complete recovery for the patients who recovered 
was 13 (±7.5) days. Recovery occurred at 9 (±1.3) 
days when one dopaminergic agonist (amantadine 
TABLE 1 
PHARMACOLOGICAL AGENTS USED IN THE 
MANAGEMENT OF THE NEUROLEPTIC 
MALIGNANT SYNDROME 
Specific drug used 
Amantadine (A) 
Bromocryptme (B) 
L- DOPA 
Dantrolene 
Anticholinergic agent 
Single Agent (A/B) 
Two Agents (A+B) 
Number 
7 
5 
2 
3 
2 
4 
4 
TABLE 2 
SHORT AND LONG TERM COMPLICATIONS SEEN IN 
PATIENTS WITH NMS. 
Complication 
Short-term (N=13) 
• Renal failure 
• Respiratory failure 
• Lithium toxicity 
•Seizures 
• Deep Vein Thrombosis 
Long term (N= 5) 
• Psychiatric 
- Affective 
- Memory disturbance 
• Neurologic 
Number 
7 
6 
2 
1 
1 
5 
1 
3 
TABLE 3 
NEUROLEPTICS USED AND OUTCOME UPON 
RE-CHALLENGE AFTER NMS 
Re-challenge (N=6) 
Neuroleptic used 
Halopendol 
Pimozide 
Chlorpomazine 
Thioridazine 
Less potent than prior neuroleptic 
Outcome 
No Complications 
Equal or more potent than prior neuroleptic 
Outcome 
forme fruste' NMS 
Severe EPS 
No complications 
Number 
2 
1 
2 
1 
2 
2 
4 
1 
1 
2 
or bromocriptine) had been used singly for 
treatment, compared to 17 (±8.4) days when two 
agents (both amantadine and bromocriptine) were 
used to treat the episode (p=0.07, NS). 
Short and long-term complications 
developed by these patients are listed in table 
2. Long term follow-up data was available for 
five of the patients who survived (63%). The 
mean duration follow-up was eight (range: 1-15) 
months. Patients were noticed to develop chronic 
and recurrent affective episodes different from 
their original illness, and neurologic 
complications included disturbances in muscle 
tone, gait and adventitious movements. 
Re-challenge was attempted in six of the 
eight (75%) patients who recovered. Two of the 
six patients (33%) experienced significant side 
effects upon re-challenge. Drugs used for re-
challenge, and the outcomes thereof are shown 
in table 3 The mean time to re-challenge was 
74 2 days (range: 2-210) The neuroleptic loading 
rate on rechallenge ranged from 0.04 to 1.25 CPZ-
Eq/day, with a mean (± SD) of 0.46 (±0.46). This 
was statistically not significantly different from the 
loading rate preceding the NMS in these patients 
(Mean+SD= 0 93 + 0.92. t=0.5. NS). Two of the 
four patients re-challenged with a high potency 
neuroleptic experienced partial recurrence of the 
syndrome characterized by severe extra-
pyramidal symptoms (EPS) in one case and 
'forme fruste' NMS, characterized by EPS and 
autonomic symptoms without fever in the other. 
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Both these patients had received neuroleptics at 
'high' loading rates (0.75 and 1.25 CPZ-Eq/day). 
DISCUSSION 
Literature about the treatment, 
complications and rechalienge after NMS is 
scanty because the infrequency of the condition. 
A lot of our understanding is based on reviews 
(Caroff and Mann, 1993) and meta-analysis (Shalev 
and Munitz,1986; Shalev et al.,1989) of case 
reports and series. Studying all cases at a centre 
over a period of time allows systematic 
examination of different aspects of the syndrome 
as it occurs during naturalistic treatment. Certain 
other important features of this study deserve 
mention. The cases were identified by a thorough 
search of elaborate ICU records. Information about 
the cases was collected on a detailed Proforma 
allowing for this closer evaluation. In addition, our 
study is among the few that have systematically 
examined rechalienge with conventional 
neuroleptics after NMS (Rosebush et al.,1989, 
Pope et al.,1991). Hence, this paper makes an 
important contribution to the literature about the 
Neuroleptic Malignant Syndrome. 
Almost all patients developed acute 
medical complications during the episode of 
NMS, most frequently in the form of renal or 
pulmonary failure. Myoglobinuria from acute 
muscle necrosis and hypoxemia on blood gas 
analysis are described in literature as frequently 
occurring complications during NMS (Caroff and 
Mann, 1993). These were also eventually the 
causes of death for patients with a fatal outcome 
(Chopra etal.,1999). This underscores the need 
for adequate medical supervision and 
management of patients when they develop NMS. 
The high incidence of medical problems in these 
patients is one indicator that the cases of NMS 
diagnosed were probably the most severe ones. 
Also, both patients on concomitant lithium therapy 
developed signs of lithium toxicity as well. This 
pattern of increased toxicity of the lithium-
neuroleptic combination has also been described 
in literature (Spring and Frankel,1981). 
Long-term complications like cognitive and 
neurological disturbances, noticed in our patients 
were similar to those described earlier in literature 
(Koponen et al.,1991; Rothke and Bush,1986). 
However, all patients for whom long-term follow-
up documentation is available show the 
occurrence of recurrent affective-like episodes in 
these patients, which has not been described 
before. Whether this represents exacerbation of 
an earlier condition or the development of a new 
'organic' condition is difficult to comment at this 
point. It is in contrast to the finding of an earlier 
study by Levenson and Fisher (1988) which found 
no change in the patient's psychiatric condition 
after NMS. It is likely that the patients remained 
in contact with health services because of these 
episodes, and hence information about them was 
available. This finding deserves closer examination. 
An important finding of our study is with 
regard to the treatment of NMS, which in our 
setting was naturalistic i.e. at the discretion of 
the treating psychiatrist. Every patient in our 
series received some pharmacological 
intervention in addition to supportive care. 
However, patients treated with two dopamine 
agonists had a longer time to recovery than those 
treated with one either amantadine or 
bromocriptine alone This finding calls into 
question the results of a recently published 
review (Davis et al.,2000) which found dopamine 
agonists to be useful in the management of NMS. 
It is however, similar to a related finding by 
Rosebush et al. (1991) where patients treated 
with bromocriptine or dantrolene had a more 
prolonged course of illness when compared to 
those receiving supportive care alone 
However, as this finding was difficult to 
explain, we re-examined our database for a 
possible explanation A finding in our earlier 
paper (Chopra et al., 1999) was that NMS lasted 
about eighteen days when resulting from depot 
neuroleptics compared to nine days from short 
acting preparations On re-examination, we 
found that in some instances patients developing 
NMS from depot neuroleptics had a protracted 
course, and hence had a second dopaminergic 
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agent added on with the hope of achieving an earlier 
remission Hence, the possibility exists that a 
longer than expected duration of NMS was the 
cause why two agents were used during treatment, 
and not the effect However, our data does not 
allow us to comment about any benefit from the 
use of these agents. Future studies and reviews 
need to closely examine the question of benefit 
from dopaminergic agonists for the treatment of 
NMS in the light of such findings. 
Numerous studies have demonstrated the 
safety of re-challenge following NMS (Levenson 
and Fisher, 1988, Rosebush et al., 1989, Pope et 
al.,1991) Re-challenge was attempted in a 
significant portion (75%) of the patients in our 
series who recovered Certain significant findings 
also emerge from this data. A conventional 
neuroleptic of equal or even greater potency than 
the one causing NMS was used during re-
challenge for four of the six patients (66%). Two 
of these patients for whom high neuroleptic loading 
rates were used developed partial recurrence of 
the syndrome Hence, it appears that a 
combination of high potency neuroleptic 
administered at a rapid loading rate appears to 
be crucial for the recurrence of NMS on re-
challenge. Conversely, half the patients re-
challenged with high potency neuroleptic were able 
to tolerate the challenge when attempted 
cautiously This questions the notion that only a 
lower potency neuroleptic should be used for re-
challenge, although it would be judicious practice 
to use a neuroleptic of lesser potency when one 
is available. 
The rarity and heterogeneity of the 
neuroleptic malignant syndrome limit the 
feasibility of conducting clinical trials for this 
disorder Any study at a single centre is likely to 
suffer from the limitation of a small sample size. 
Comparison between small samples may cause 
real differences to be missed (type II errors). For 
example, in this study, the mean loading rates on 
re-challenge were about half those that resulted 
in NMS, but the difference failed to reach 
statistical significance Another limitation lies in 
the process of case selection and the study's 
retrospective design. The possibility exists that 
milder cases of NMS were not admitted to the 
ICU and hence not included in the study. 
Nonetheless, our study raises some important 
questions for future investigation, and can serve 
to increase awareness, leading to better 
management of NMS. 
ACKNOWLEDGEMENT 
The authors wish to thank Dr. D.K. 
Subbakrishna, Ph.D., Department of 
Biostatistics, NIMHANS, for his help with 
statistical calculations. 
REFERENCES 
Caroff.S.N. & Mann.S.C. (1988) 
Neuroleptic malignant syndrome. 
Psychopharmacology Bulletin, 24, 25-29. 
Caroff,S.N. & Mann.S.C. (1993) 
Neuroleptic malignant syndrome. Medical Clinics 
of North America, 77, 185-202. 
Chopra,M.P., Prakash.S.S. & Raguram, 
R. (1999) The neuroleptic malignant syndrome: 
An Indian experience. Comprehensive 
Psychiatry, 40, 19-23. 
Davis.J.M., Caroff.S.N. & Mann.S.C. 
(2000) Treatment of the neuroleptic malignant 
syndrome Psychiatric Annals, 30, 325-331. 
Koponen,H., Repo,E. & Lepola.U. 
(1991) Long-term outcome after neuroleptic 
malignant syndrome. Acta Psychiatrica 
Scandinavica, 84, 550- 551. 
Levenson,J.L. & Fisher.J G. (1988) 
Long-term outcome after neuroleptic malignant 
syndrome Journal of Clinical Psychiatry, 49, 
154-156. 
Pope.H.G., Aizley.H.G. & Keck.P.E. 
(1991) Neuroleptic malignant syndrome: Long-
44 RECOVERY AND RECHALLENGE AFTER NMS 
term follow-up of 20 cases. Journal of Clinical 
Psychiatry, 52, 208-212. 
Rosebush,P.I., Stewart, T.D. & 
Gelenberg.A.J. (1989) Twenty neuroleptic 
rechallenges after neuroleptic malignant 
syndrome in 15 patients. Journal of Clinical 
Psychiatry, 50, 295-298. 
Rosebush,P.I., Stewart.T. & Mazurek, 
M.F. (1991) The treatment of the neuroleptic 
malignant syndrome: Are dantrolene and 
bromocryptine useful adjuncts to supportive 
care? British Journal of Psychiatry, 159, 709-712. 
Rothke.S. & Bush.D. (1986) Neuropsy-
chological sequelae of neuroleptic malignant 
syndrome. Biological Psychiatry, 21, 838-841. 
Shalev.A., Hermesh.H. & Munitz, 
H. (1989) Mortality from neuroleptic malignant 
syndrome. Journal of Clinical Psychiatry, 
50,18-25. 
Shalev.A. & Munitz,H. (1986) The 
neuroleptic malignant syndrome: Agent and host 
interaction. Acta Psychiatrica Scandinavica, 73, 
337-347. 
Spring,G. & Frankel.M. (1981) New data 
on lithium and haloperidol incompatibility. 
American Journal of Psychiatry, 138, 818-821. 
MOHITP CHOPRA'. MD. DPM. Resident & R. RAGURAM. MD. Associate Professor. Department of Psychiatry, National 
Institute of Mental Health and Neuro Sciences. HosurRoad, Bangalore, 560 029 ('Psychiatry. 8thfloor, University of Pennsylvania 
Health System. 3600 Market Street. Philadelphia. PA 19104, USA). 
' Correspondence 
45 